Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older
![Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40121-023-00864-4/MediaObjects/40121_2023_864_Fig5_HTML.png)
![](https://www.tandfonline.com/cms/asset/eb916253-a949-4a0a-8dbd-9d58c634dd91/khvi_a_2251825_f0001_b.gif)
Full article: Real-world impact and effectiveness of MenACWY-TT
Full article: Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study
![](https://0.academia-photos.com/attachment_thumbnails/101058172/mini_magick20230413-1-idoju.png?1681417881)
PDF) A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years
![](https://www.tandfonline.com/cms/asset/a88c6118-9124-4e1c-8680-b9fe7d19296f/khvi_a_2099142_f0004_b.gif)
Full article: Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
![](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12889-020-09946-1/MediaObjects/12889_2020_9946_Fig3_HTML.png)
Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs, BMC Public Health
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20210223191333153-0311:S0950268821000261:S0950268821000261_tab3.png?pub-status=live)
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine
![](https://i1.rgstatic.net/publication/374237053_Structured_Benefit-Risk_Assessment_of_a_New_Quadrivalent_Meningococcal_Conjugate_Vaccine_MenACYW-TT_in_Individuals_Ages_12_Months_and_Older/links/65157202f91aee386e7452dc/largepreview.png)
PDF) Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older
![](https://www.mdpi.com/microorganisms/microorganisms-08-01521/article_deploy/html/images/microorganisms-08-01521-g003.png)
Microorganisms, Free Full-Text
![](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2F1471-2458-11-S3-S29/MediaObjects/12889_2011_Article_2965_Fig3_HTML.jpg)
An evaluation of emerging vaccines for childhood meningococcal disease, BMC Public Health
![](https://www.researchgate.net/publication/367055726/figure/fig2/AS:11431281126788148@1678818776514/hSBA-vaccine-seroresponse-a-after-a-booster-dose-of-MenACYW-TT-at-a-Day-30-PPAS1-for.png)
hSBA vaccine seroresponse a after a booster dose of MenACYW-TT at (a)